Bispecific antibodies targeting nkp46 and gpc3 (Cytovia Therapeutics)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameBispecific antibodies targeting nkp46 and gpc3 (Cytovia Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of Actionanti natural cytotoxicity triggering receptor 1Anti-Glypican-3
TargetsNatural cytotoxicity triggering receptor 1Glypican-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCytovia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytovia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A